{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:17:03Z","timestamp":1789503423457,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009342","name":"Aeras","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009342","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.vaccine.2015.02.004","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T06:28:20Z","timestamp":1424154500000},"page":"1890-1896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts >350 cells\/mm3"],"prefix":"10.1016","volume":"33","author":[{"given":"Gavin John","family":"Churchyard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret Ann","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hokey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerabadran","family":"Dheenadhayalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Bruce","family":"McClain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Pau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.02.004_bib0105","series-title":"WHO\/HTM\/TB\/2013.11","article-title":"Global tuberculosis report 2013","author":"World Health Organisation","year":"2012"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0110","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1016\/j.vaccine.2011.05.023","article-title":"Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial","volume":"29","author":"Barreto","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0115","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S0140-6736(05)67145-0","article-title":"Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial","volume":"366","author":"Rodrigues","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0120","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.vaccine.2012.01.048","article-title":"A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity","volume":"30","author":"Hoft","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0125","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1164\/rccm.200910-1484OC","article-title":"The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults","volume":"181","author":"Abel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jim.2004.06.010","article-title":"Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies","volume":"291","author":"Hanekom","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0135","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/JCM.41.11.5046-5052.2003","article-title":"Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors","volume":"41","author":"Sprangers","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0140","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1016\/j.vaccine.2014.09.001","article-title":"The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8 T cell responses","volume":"32","author":"Kagina","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1615\/CritRevImmunol.v26.i4.30","article-title":"Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity","volume":"26","author":"Woodworth","year":"2006","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0150","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CDLI.11.2.351-357.2004","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0160","doi-asserted-by":"crossref","first-page":"e78679","DOI":"10.1371\/journal.pone.0078679","article-title":"A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age","volume":"8","author":"Ouedraogo","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0165","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","article-title":"Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine","volume":"24","author":"von Reyn","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0170","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1164\/rccm.201108-1548OC","article-title":"A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and\/or Mycobacterium tuberculosis-infected adults","volume":"185","author":"Scriba","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0175","doi-asserted-by":"crossref","first-page":"e89612","DOI":"10.1371\/journal.pone.0089612","article-title":"Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection","volume":"9","author":"Nell","year":"2014","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.vaccine.2015.02.004_bib0180","doi-asserted-by":"crossref","first-page":"e114602","DOI":"10.1371\/journal.pone.0114602","article-title":"Safety and Immunogenicity of H1\/IC31(R), an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells\/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial","volume":"9","author":"Reither","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0185","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMoa1407380","article-title":"Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis","volume":"371","author":"Mayosi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0190","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.1016\/j.vaccine.2010.09.041","article-title":"Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania","volume":"28","author":"Lahey","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0195","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/eji.200939754","article-title":"Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells","volume":"40","author":"Scriba","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2015.02.004_bib0200","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","article-title":"Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial","volume":"31","author":"Leroux-Roels","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1500170X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1500170X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T01:45:21Z","timestamp":1598751921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1500170X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":20,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0264410X1500170X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.02.004","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts >350 cells\/mm3","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}